Originally published as JCO Early Release 10.1200/JCO.2006.05.7406 on November 6 2006

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rousseau, C. Articles by Campone, M. Search for Related Content PubMed PubMed Citation Articles by Rousseau, C. Articles by Campone, M. Social Bookmarking                            What's this?

Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography

Caroline Rousseau, Anne Devillers, Christine Sagan, Ludovic Ferrer, Boumédiène Bridji, Loïc Campion, Myriam Ricaud, Emmanuelle Bourbouloux, Isabelle Doutriaux, Martine Clouet, Dominique Berton-Rigaud, Catherine Bouriel, Valérie Delecroix, Etienne Garin, Sophie Rouquette, Isabelle Resche, Pierre Kerbrat, Jean François Chatal, Mario Campone

From the Nuclear Medicine, Pathology, Radiophysics, Statistics, Radiology, and Medical Oncology Units, René Gauducheau Cancer Center; Research Cancer Center, Nantes University, Inserm U601, Nantes, France; Nuclear Medicine, Radiology, and Medical Oncology Units, Eugène Marquis Cancer Center; and Gynecologic Surgery Unit, University Hospital Pontchaillou, Rennes, France

Address reprint requests to Caroline Rousseau, Service de Médecine Nucléaire, Centre René Gauducheau, Blvd Monod, 44805 Saint Herblain Cedex, France; e-mail: c-rousseau{at}nantes.fnclcc.fr

PURPOSE: This study aimed to assess prospectively the efficacy of sequential [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG PET) to evaluate early response to neoadjuvant chemotherapy in stage II and III breast cancer patients.

PATIENTS AND METHODS: Images were acquired with a PET/computed tomography scanner in 64 patients after administration of FDG (5 MBq/kg) at baseline and after the first, second, third, and sixth course of chemotherapy. Ultrasound and mammography were used to assess tumor size. Decrease in the standardized uptake value (SUV) with PET was compared with the pathologic response.

RESULTS: Surgery was performed after six courses of chemotherapy and pathologic analysis revealed gross residual disease in 28 patients and minimal residual disease in 36 patients. Although SUV data did not vary much in nonresponders (based on pathology findings), they decreased markedly to background levels in 94% (34 of 36) of responders. When using 60% of SUV at baseline as the cutoff value, the sensitivity, specificity, and negative predictive value of FDG PET were 61%, 96%, and 68% after one course of chemotherapy, 89%, 95%, and 85% after two courses, and 88%, 73%, and 83% after three courses, respectively. The same parameters with ultrasound (US) and mammography were 64%, 43%, and 55%, and 31%, 56%, and 45%, respectively. Assessment of tumor response with US or mammography was never significant whatever the cutoff.

CONCLUSION: Pathologic response to neoadjuvant chemotherapy in stage II and III breast cancer can be predicted accurately by FDG PET after two courses of chemotherapy.

published online ahead of print at www.jco.orgon November 6, 2006.

Supported by Conseil Régional des Pays de Loire.

Presented in poster format at the 41st Annual Meeting of the American Society of Clinical Oncology, May 13-17, 2005, Orlando, FL; and at the 52nd Annual Meeting of the Society of Nuclear Medicine, June 17-23, 2005, Toronto, Canada.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. L. Bowen, Y. Wu, A. J. Chaudhari, L. Fu, N. J. Packard, G. W. Burkett, K. Yang, K. K. Lindfors, D. K. Shelton, R. Hagge, et al. Initial Characterization of a Dedicated Breast PET/CT Scanner During Human Imaging J. Nucl. Med., September 1, 2009; 50(9): 1401 - 1408. [Abstract] [Full Text] [PDF]

				S. Jiang, B. W. Pogue, C. M. Carpenter, S. P. Poplack, W. A. Wells, C. A. Kogel, J. A. Forero, L. S. Muffly, G. N. Schwartz, K. D. Paulsen, et al. Evaluation of Breast Tumor Response to Neoadjuvant Chemotherapy with Tomographic Diffuse Optical Spectroscopy: Case Studies of Tumor Region-of-Interest Changes Radiology, August 1, 2009; 252(2): 551 - 560. [Abstract] [Full Text] [PDF]

				G. Frasci, P. Comella, M. Rinaldo, G. Iodice, M. Di Bonito, M. D'Aiuto, A. Petrillo, S. Lastoria, C. Siani, G. Comella, et al. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer Ann. Onc., July 1, 2009; 20(7): 1185 - 1192. [Abstract] [Full Text] [PDF]

				J. H. Lee, E. L. Rosen, and D. A. Mankoff The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 2--Response to Therapy, Other Indications, and Future Directions J. Nucl. Med., May 1, 2009; 50(5): 738 - 748. [Abstract] [Full Text] [PDF]

				N. Avril, S. Sassen, and R. Roylance Response to Therapy in Breast Cancer J. Nucl. Med., May 1, 2009; 50(Suppl_1): 55S - 63S. [Abstract] [Full Text] [PDF]

				M. R. Benz, J. Czernin, M. S. Allen-Auerbach, W. D. Tap, S. M. Dry, D. Elashoff, K. Chow, V. Evilevitch, J. J. Eckardt, M. E. Phelps, et al. FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after the Initial Cycle of Neoadjuvant Chemotherapy in High-Grade Soft-Tissue Sarcomas Clin. Cancer Res., April 15, 2009; 15(8): 2856 - 2863. [Abstract] [Full Text] [PDF]

				M. Allen-Auerbach and W. A. Weber Measuring Response with FDG-PET: Methodological Aspects Oncologist, April 1, 2009; 14(4): 369 - 377. [Abstract] [Full Text] [PDF]

				J. Schwarz-Dose, M. Untch, R. Tiling, S. Sassen, S. Mahner, S. Kahlert, N. Harbeck, A. Lebeau, W. Brenner, M. Schwaiger, et al. Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [18F]Fluorodeoxyglucose J. Clin. Oncol., February 1, 2009; 27(4): 535 - 541. [Abstract] [Full Text] [PDF]

				S. Ben-Haim and P. Ell 18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response J. Nucl. Med., January 1, 2009; 50(1): 88 - 99. [Abstract] [Full Text] [PDF]

				L. K. Dunnwald, J. R. Gralow, G. K. Ellis, R. B. Livingston, H. M. Linden, J. M. Specht, R. K. Doot, T. J. Lawton, W. E. Barlow, B. F. Kurland, et al. Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer J. Clin. Oncol., September 20, 2008; 26(27): 4449 - 4457. [Abstract] [Full Text] [PDF]

				M. R. Benz, V. Evilevitch, M. S. Allen-Auerbach, F. C. Eilber, M. E. Phelps, J. Czernin, and W. A. Weber Treatment Monitoring by 18F-FDG PET/CT in Patients with Sarcomas: Interobserver Variability of Quantitative Parameters in Treatment-Induced Changes in Histopathologically Responding and Nonresponding Tumors J. Nucl. Med., July 1, 2008; 49(7): 1038 - 1046. [Abstract] [Full Text] [PDF]

				C. Plathow and W. A. Weber Tumor Cell Metabolism Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S. [Abstract] [Full Text] [PDF]

				U. Tateishi, C. Gamez, S. Dawood, H. W. D. Yeung, M. Cristofanilli, and H. A. Macapinlac Bone Metastases in Patients with Metastatic Breast Cancer: Morphologic and Metabolic Monitoring of Response to Systemic Therapy with Integrated PET/CT Radiology, April 1, 2008; 247(1): 189 - 196. [Abstract] [Full Text] [PDF]

				S.-L. Song, J.-J. Liu, G. Huang, Z.-H. Wang, Y.-Y. Song, X.-G. Sun, and T. Chen Changes in 18F-FDG Uptake Within Minutes After Chemotherapy in a Rabbit VX2 Tumor Model J. Nucl. Med., February 1, 2008; 49(2): 303 - 309. [Abstract] [Full Text] [PDF]

				V. Evilevitch, W. A. Weber, W. D. Tap, M. Allen-Auerbach, K. Chow, S. D. Nelson, F. R. Eilber, J. J. Eckardt, R. M. Elashoff, M. E. Phelps, et al. Reduction of Glucose Metabolic Activity Is More Accurate than Change in Size at Predicting Histopathologic Response to Neoadjuvant Therapy in High-Grade Soft-Tissue Sarcomas Clin. Cancer Res., February 1, 2008; 14(3): 715 - 720. [Abstract] [Full Text] [PDF]

				M. Kaufmann, G. von Minckwitz, H. D. Bear, A. Buzdar, P. McGale, H. Bonnefoi, M. Colleoni, C. Denkert, W. Eiermann, R. Jackesz, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006 Ann. Onc., December 1, 2007; 18(12): 1927 - 1934. [Abstract] [Full Text] [PDF]

				E. L. Rosen, W. B. Eubank, and D. A. Mankoff FDG PET, PET/CT, and Breast Cancer Imaging RadioGraphics, October 1, 2007; 27(suppl_1): S215 - S229. [Abstract] [Full Text] [PDF]